Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S254010, C514S414000, C514S378000, C514S365000, C514S255050, C514S343000, C514S235500, C546S279100, C546S208000, C548S537000, C548S465000, C548S247000, C548S204000, C544S372000, C544S141000, C544S405000
Reexamination Certificate
active
07977371
ABSTRACT:
Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease. In the formula, the ring A represents a benzene ring or the like; R1represents a halogen atom, a hydrogen atom, a lower alkyl group or the like; R2represents a halogen atom, a lower alkyl group which may have a substituent, a lower alkenyl group, a lower alkynyl group which may have a substituent, a lower cycloalkyl group, an aryl group, a hydroxy group, a lower alkoxy group which may have a substituent or the like; and n represents 0, 1, 2, 3 or the like.
REFERENCES:
patent: 7015218 (2006-03-01), Ushio et al.
patent: 2001/0020034 (2001-09-01), Larson et al.
patent: WO 98/52558 (1998-11-01), None
patent: WO 00/71532 (2000-11-01), None
patent: WO 03/086371 (2003-10-01), None
patent: WO 2005/113534 (2005-12-01), None
patent: WO 2005/123671 (2005-12-01), None
Bessatsu Igaku no Agumi (Journal of Clinical and Experimental Medicine, Supplement) Cytokines, Iso kara Risho Oyo made (from Basic to Clinical Research) pp. 28-35 (1992) (with translation of relevant portion, p. 31, Table 1).
K. Izumi et al, “Suppression of Choroidal Neovascularization by Blocking Interleukin-6 Receptor Signaling”Invest. Ophthalmol. Vis. Sci., 47, E-Abstract 905 (2006).
N. Namura et al, “Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients . . .”,Diabetes Res. Clin. Pract., 61, pp. 93-101 (2003).
H. Funatsu et al, “Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor Are Related to Diabetic Macular Edema”,Ophthamology, 110, pp. 1690-1696 (2003).
STN Registry files CAS No. 375823-41-9, 2001.
M.T. Garcia-Lopez et al, “New Routes for the Sunthesis of Pyrrolo-[3,2-d]-pyrimidine Systems Starting from a Common Pyrrole Derivative”,J. Chem. Soc. Perkin Transactions 1, 5, pp. 483-487 (1978).
Communication dated Jul. 14, 2010 (7 pages) in EP 08 72 0883 including the International Search Report and European Search Opinion.
Enomoto Hiroshi
Inaba Takaaki
Ishizaka Noriko
Kawashima Kenji
Kudou Kazuhiro
Coughlin Matthew
Holtz Holtz Goodman & Chick PC
Kosack Joseph
Santen Pharmaceutical Co. Ltd.
LandOfFree
Pyrrole derivative having ureido group and aminocarbonyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole derivative having ureido group and aminocarbonyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole derivative having ureido group and aminocarbonyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722354